#Africa

Abbott researchers found a high proportion of elite HIV controllers in the Democratic Republic of Congo, which could lead to cure insights.

This finding among sub-Saharan Africans is quite concerning since dolutegravir is now the preferred first-line HIV treatment worldwide.

UNAIDS hopes nations will follow the lead of a number of sub-Saharan African countries that are gaining control of their HIV epidemics.

The company also has plans to study monthly islatravir’s efficacy as HIV prevention among men who have sex with men.

Long-acting injectable cabotegravir for HIV prevention could hit the market for men and women in early 2022.

More studies link dolutegravir and other drugs to weight gain among people with HIV.

The REPRIEVE study, which is primarily looking at a statin’s effect on cardiovascular disease, is shedding light on many other mysteries.

Previously, kids weighing 44 to 88 pounds had to take lower doses—which are less available worldwide—and do so more than once a day.

Researchers found a strong association between the criminalization of sex between men and higher HIV rates in gay and bi men.

The SEARCH study included men and women at elevated risk of HIV in Kenya and Uganda.

A 2018 report had suggested that HIV-positive women’s use of the drug at conception increased the risk of the rare birth defects.

The placebo-controlled trial compared injections of cabotegravir given every eight weeks versus daily Truvada as PrEP.

Disruptions in access to antiretroviral treatment due to the COVID-19 pandemic could lead to a major setback in combating HIV.

Antiretrovirals likely drive up rates, both directly and by helping people live long enough to develop high blood pressure.

The agency has also lowered the weight threshold for film-coated tablets of the integrase inhibitor.

Having an undetectable viral load did not change the risk, which nevertheless was not as severe as the risk tied to diabetes.